LUND, Sweden — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has raised $1.25 million USD (10.5 million SEK) seed capital from international investors.
Participants in the round include serial biotech entrepreneurs and investors Christer Fåhraeus (CellaVision, Flatfrog, EQL Pharma) and Simon Fredriksson (Olink, Genagon Therapeutics), and investment groups led by Torna Kapital, LU Holding, as well as the Gunnar Nilsson Cancer Foundation, among others.
This round of funding will be used to expand SAGA’s enterprise and team to meet the increased demand for ultrasensitive cancer detection products and services.
“This is an exciting step for SAGA. We are pleased to be working with experienced life science business angels and syndicates, and are confident that these funds will allow us to meet key milestones as we grow revenues and deliver our revolutionary technologies to aid patients with cancer.” – Lao Saal, Founder and CEO SAGA Diagnostics.
Additionally, SAGA announces the appointment of a new Director of Corporate and Business Development, Åke Nilsson, a veteran business strategist and dealmaker with 30 years corner office pharma and life science experience.
“Åke is a terrific addition to the team, and we look forward to accelerating our growth through strategic partnerships worldwide.” – Anthony George, Co-Founder and CTO.
SAGA Diagnostics is a company in the SmiLe incubator, an incubator that helps life science entrepreneurs with business coaching and laboratory facilities. www.smileincubator.life
Contact: CEO Lao Saal, M.D. Ph.D. firstname.lastname@example.org Phone: +46 (0)70 - 888 52 61
About SAGA Diagnostics
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.